Clinical Trials Logo

Clinical Trial Summary

Severe Acute Respiratory Syndrome (SARS) is a newly recognized illness that can be fatal.

The purpose of this study is to better understand SARS by collecting samples of blood and other body fluids of people who have been exposed to SARS or who are suspected to have the illness.

Up to 300 volunteers aged 18 years or older will be enrolled in this study. Participants will donate blood samples and, if appropriate, samples of fluid from the lungs, nose, or throat. Researchers will test these samples for proteins that control or mediate inflammatory or immune responses. The patterns of these proteins will reveal how SARS affects the body and the efforts the body makes to fight off the infection.


Clinical Trial Description

Severe acute respiratory syndrome (SARS) is a newly recognized illness associated with substantial mobidity and mortality. Patients develop fever followed by rapidly progressive and even fatal respiratory disease. SARS is associated with infection with a novel coronavirus. The evaluation of the inflammatory responses evoked by SARS may yield information regarding its pathogenesis and help with patient management. This protocol, then, merely aims to study disease pathogenesis and natural history, by studying samples and data that are collected by outside physicians or physicians at the Clinical Center and sent for evaluation of the inflammatory response. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00066209
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase N/A
Start date August 4, 2003
Completion date May 24, 2007

See also
  Status Clinical Trial Phase
Completed NCT04527614 - Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection N/A
Not yet recruiting NCT04357613 - IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS. Phase 2
Completed NCT04453384 - Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia Phase 2
Enrolling by invitation NCT04363047 - Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19
Completed NCT04383535 - Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia N/A
Completed NCT04567927 - Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With COVID-19
Recruiting NCT04381819 - Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19
Recruiting NCT03443102 - Long-term Assessment of Organ Functions Among Survivors of Severe Acute Respiratory Syndrome N/A